Skip to main content
Michael Fradley, MD, Cardiology, Philadelphia, PA

MichaelGFradleyMD

Cardiology Philadelphia, PA

Cardiac Electrophysiology

Medical Director, Penn Cardio-Oncology, Associate Professor of Clinical Medicine

Dr. Fradley is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Fradley's full profile

Already have an account?

  • Office

    3400 Civic Center Blvd -- PCAM
    3rd Floor
    Philadelphia, PA 19104
    Phone+1 215-662-7700
    Fax+1 215-349-5533

Education & Training

  • Massachusetts General Hospital
    Massachusetts General HospitalFellowship, Clinical Cardiac Electrophysiology, 2011 - 2012
  • Massachusetts General Hospital
    Massachusetts General HospitalFellowship, Cardiovascular Disease, 2008 - 2011
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 2005 - 2008
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 2005

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2020 - 2024
  • FL State Medical License
    FL State Medical License 2013 - 2021
  • MA State Medical License
    MA State Medical License 2008 - 2014
  • American Board of Internal Medicine Cardiovascular Disease
  • American Board of Internal Medicine Clinical Cardiac Electrophysiology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2013

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • [Board 304] Patterns of Anticoagulation Use in Cancer Patients With Atrial Fibrillation and/or Atrial Flutter
    Michael Fradley, 2019 ACC Scientific Session & Expo, New Orleans, New Orleans, 3/17/2019

Press Mentions

  • Lung Cancer Drug Osimertinib Tied to Cardiac Events, Even in Low-Risk Patients
    Lung Cancer Drug Osimertinib Tied to Cardiac Events, Even in Low-Risk PatientsDecember 12th, 2024
  • Heart Failure Risk Lingers Long After Chemotherapy, Regardless of Dose
    Heart Failure Risk Lingers Long After Chemotherapy, Regardless of DoseFebruary 3rd, 2023
  • Cardio-Oncology Topics from AHA 2020
    Cardio-Oncology Topics from AHA 2020August 17th, 2021
  • Join now to see all

Professional Memberships